Literature DB >> 25725813

Intensity-modulated radiotherapy and volumetric-modulated arc therapy have distinct clinical advantages in non-small cell lung cancer treatment.

Jun Zhang1, Xiao-Ling Yu, Guo-Feng Zheng, Fei Zhao.   

Abstract

This study was conducted to compare the efficacy of intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) in delivering the planned dosage in the treatment of non-small cell lung cancer (NSCLC). Between September 2013 and March 2014, 125 NSCLC patients were randomly chosen and allocated to the IMRT group (n = 65) and VMAT group (n = 60). We compared multiple parameters such as target dose, organ dosimetry, monitor unit (MU) and time of therapy between IMRT and VMAT groups. The prescribed dose coverage of both planning techniques was 95 % of the planning target volumes (PTVs). PTV 95 % and homogeneous index in IMRT plan were greater than those in VMAT plan (both P < 0.05), while no significant difference in conformity index was observed (P > 0.05). The mean total lung V5 and V10 in VMAT group were markedly higher than those in IMRT group, but the V20, V30, and V40 in VMAT group were significantly lower (all P < 0.05), but no statistically significant difference was observed in V15 and V20 (P > 0.05). Furthermore, the planning spine and esophagus at risk volume showed no statistical significances in both groups (P > 0.05). MU of IMRT plan was about 4.2 % less than that of VMAT plan, which was statistically significant (P < 0.001). Both IMRT and VMAT had significant advantages in the treatment of NSCLC. The IMRT may be better for NSCLC patients with poor pulmonary function, and VMAT may be recommended for NSCLC patients with normal pulmonary function.

Entities:  

Mesh:

Year:  2015        PMID: 25725813     DOI: 10.1007/s12032-015-0546-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  33 in total

1.  Volumetric modulated arc therapy for nasopharyngeal carcinoma: a dosimetric comparison with TomoTherapy and step-and-shoot IMRT.

Authors:  Szu-Huai Lu; Jason Chia-Hsien Cheng; Sung-Hsin Kuo; Jason Jeun-Shenn Lee; Liang-Hsin Chen; Jian-Kuen Wu; Yu-Hsuan Chen; Wan-Yu Chen; Shu-Yu Wen; Fok-Ching Chong; Chien-Jang Wu; Chun-Wei Wang
Journal:  Radiother Oncol       Date:  2012-01-09       Impact factor: 6.280

2.  On the possible benefits of a hybrid VMAT technique in the treatment of non-small cell lung cancer.

Authors:  John Agapito
Journal:  Med Dosim       Date:  2013-10-04       Impact factor: 1.482

3.  Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer.

Authors:  Fen Yun; Yongfeng Jia; Xiuxia Li; Li Yuan; Qinnuan Sun; Huiling Yu; Lin Shi; Hongwei Yuan
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

4.  Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes.

Authors:  Joke Werbrouck; Kim De Ruyck; Fréderic Duprez; Liv Veldeman; Kathleen Claes; Marc Van Eijkeren; Tom Boterberg; Petra Willems; Anne Vral; Wilfried De Neve; Hubert Thierens
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-15       Impact factor: 7.038

5.  The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis.

Authors:  Wen-Liang Chen; Kuang-Tai Kuo; Teh-Ying Chou; Chien-Lung Chen; Chih-Hao Wang; Yau-Huei Wei; Liang-Shun Wang
Journal:  BMC Cancer       Date:  2012-06-29       Impact factor: 4.430

6.  Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer.

Authors:  Min-Jeong Kim; Seung-Gu Yeo; Eun Seok Kim; Chul Kee Min; Pyung Se An
Journal:  Oncol Lett       Date:  2012-12-18       Impact factor: 2.967

7.  The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer.

Authors:  Xiang-hua Liu; Zhi-li Liu; Ming Sun; Jing Liu; Zhao-xia Wang; Wei De
Journal:  BMC Cancer       Date:  2013-10-08       Impact factor: 4.430

8.  Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.

Authors:  Ning Zhu; Yi Gong; Jian He; Jingwen Xia; Xiaodong Chen
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

9.  A treatment planning study comparing Elekta VMAT and fixed field IMRT using the varian treatment planning system eclipse.

Authors:  Samuel Peters; Hans Schiefer; Ludwig Plasswilm
Journal:  Radiat Oncol       Date:  2014-07-10       Impact factor: 3.481

10.  Applying the technique of volume-modulated arc radiotherapy to upper esophageal carcinoma.

Authors:  Pan Ma; Xiaozhen Wang; Yingjie Xu; Jianrong Dai; Luhua Wang
Journal:  J Appl Clin Med Phys       Date:  2014-05-08       Impact factor: 2.102

View more
  4 in total

1.  Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry.

Authors:  Pierre Truntzer; Delphine Antoni; Nicola Santelmo; Catherine Schumacher; Pierre-Emmanuel Falcoz; Elisabeth Quoix; Gilbert Massard; Georges Noël
Journal:  Rep Pract Oncol Radiother       Date:  2016-05-05

2.  Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer.

Authors:  Yujin Xu; Jianqiang Li; Jin Wang; Xiao Hu; Honglian Ma; Pu Li; Xiao Zheng; Ming Chen
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

3.  Toxicity after volumetric modulated arc therapy for lung cancer: a monocentric retrospective study.

Authors:  Vincent Bourbonne; Alice Delafoy; François Lucia; Gilles Quéré; Olivier Pradier; Ulrike Schick
Journal:  Transl Lung Cancer Res       Date:  2021-01

Review 4.  Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.

Authors:  John Conibear
Journal:  Br J Cancer       Date:  2020-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.